title: Rivaroxaban for the treatment of pulmonary embolism.
abstract: With the advent of new oral anticoagulants (NOACs) for the treatment of deep-vein thrombosis (DVT) and/or pulmonary embolism (PE), a new era of oral anticoagulation for patients with venous thromboembolism (VTE) has begun. Rivaroxaban is the first NOAC to receive regulatory approval for the acute and continued treatment of DVT and PE, and for the secondary prevention of VTE. Here, the clinical trials of rivaroxaban in patients with VTE are reviewed, and the clinical use of rivaroxaban for patients with PE is discussed. Even though rivaroxaban will facilitate the therapeutic management of PE, its use in specific clinical situations needs further study.
authors.affiliation: Vascular Medicine and Haemostasis, Department of Cardiovascular Sciences, KU Leuven, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium.
authors.forename: Thomas
authors.initials: T
authors.lastname: Vanassche
authors.forename: Peter
authors.initials: P
authors.lastname: Verhamme
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000627:therapeutic use*; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use*; D011655:Pulmonary Embolism / Q000188:drug therapy*; D000069552:Rivaroxaban; D013876:Thiophenes / Q000627:therapeutic use*; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000188:drug therapy*
chemical_list: D000925:Anticoagulants; D009025:Morpholines; D013876:Thiophenes; D000069552:Rivaroxaban